Filing Analysis
Axe Compute Inc. has entered into agreements with Duos Technologies Group, Inc. to secure 55 MW of new AI data center capacity across multiple U.S. locations. The deal involves expected aggregate payments exceeding $500 million and includes nonbinding term sheets for the Company to hold 49% equity in the project entities.
🚩 Red Flags
- The equity investments are based on 'nonbinding term sheets', meaning the ownership structure and capital commitment are not yet finalized.
📋 Key Facts
- Agreements signed with Duos Technologies Group, Inc. for 55 MW of AI data center capacity.
- Expected aggregate payments exceed $500 million.
- Nonbinding term sheets executed for minority equity investments in project-associated entities.
- Axe Compute Inc. is expected to hold a 49% equity interest in these entities.
Axe Compute Inc. issued an 8-K to announce its financial results for the quarterly period ended June 30, 2026. The filing includes a press release and provides definitions for non-GAAP measures, specifically Adjusted EBITDA.
🚩 Red Flags
- Heavy reliance on non-GAAP Adjusted EBITDA which excludes significant items like stock-based compensation and volatile digital asset fluctuations.
📋 Key Facts
- Reporting of financial results for the quarter ending June 30, 2026.
- Company utilizes 'Adjusted EBITDA' as a key non-GAAP metric.
- Adjusted EBITDA excludes interest, taxes, depreciation/amortization, stock-based compensation, and unrealized gains/losses on digital assets.
- The company notes that unrealized (gains) losses on digital assets include mark-to-market adjustments for digital asset holdings and receivables.
Axe Compute Inc. announced a significant five-year customer agreement valued at over $1.5 billion to deploy dedicated AI infrastructure in the United States via its 'Build' program.
🚩 Red Flags
- The scale of the contract ($1.5B) is highly significant for a micro-cap company and may represent substantial execution risk or concentration risk.
📋 Key Facts
- Agreement duration: Five years
- Total contract value: Over $1.5 billion
- Project scope: Deployment of a dedicated AI infrastructure cluster in the U.S.
- Program name: Axe Compute Build program
- Announcement date: July 27, 2026
Axe Compute Inc. announced the securing of over $1.3 billion in new customer contracts across the US and Europe via its 'Axe Compute Build' program.
📋 Key Facts
- Secured >$1.3 billion in new customer contracts.
- Contracts span geographic regions in the United States and Europe.
- The contracts were secured through the 'Axe Compute Build' program.
- Announcement date: July 22, 2026.
Axe Compute Inc. (formerly Predictive Oncology Inc.) announced a name change and ticker symbol update to AGPU, alongside an amendment to CEO Raymond F. Vennare's employment agreement involving a salary increase and equity grants.
🚩 Red Flags
- Retroactive salary increase effective from November 1, 2025, despite the amendment being dated December 10, 2025.
📋 Key Facts
- Company changed its name from Predictive Oncology Inc. to Axe Compute Inc.
- Ticker symbol changed to AGPU on Nasdaq effective December 12, 2025.
- CEO Raymond F. Vennare's annual base salary increased from $525,000 to $575,000, retroactive to November 1, 2025.
- CEO is eligible for a target bonus of 50% of his base salary on March 31, 2026.
- CEO is eligible for 20,000 restricted stock units (RSUs) vesting in full on January 1, 2026.
Predictive Oncology Inc. is changing its corporate name to Axe Compute Inc., effective December 11, 2025. The company's common stock will trade under the new ticker symbol 'AGPU' on the Nasdaq Stock Market LLC starting approximately December 12, 2025.
📋 Key Facts
- Corporate name change from Predictive Oncology Inc. to Axe Compute Inc.
- Effective date of name change: December 11, 2025
- New ticker symbol: AGPU (effective on or about December 12, 2025)
- The Board approved the Name Change and Third Amended and Restated Bylaws; no stockholder approval was required.
- CUSIP number remains unchanged.
Predictive Oncology Inc. has regained compliance with Nasdaq's stockholders' equity requirement, effectively closing its previous listing deficiency matter. However, the company is now subject to a mandatory one-year panel monitor by Nasdaq.
🚩 Red Flags
- Mandatory one-year panel monitor imposed by Nasdaq.
- Loss of standard procedural protections (no ability to provide a compliance plan or seek additional time) if another equity deficiency occurs during the monitoring period.
- History of non-compliance with stockholders' equity requirements.
📋 Key Facts
- The Company received formal notice from the Nasdaq Hearings Panel on December 1, 2025, confirming compliance with Nasdaq Listing Rule 5550(b)(1).
- A mandatory panel monitor will be imposed for a period of one year starting December 1, 2025.
- Under Listing Rule 5815(d)(4)(B), any subsequent violation of the stockholders' equity requirement during this monitoring period will result in an immediate delist determination without the possibility of a compliance plan or additional cure periods.
Predictive Oncology Inc. held its 2025 annual meeting of stockholders on November 25, 2025, where shareholders approved several key proposals including director elections and an amendment to the equity incentive plan.
🚩 Red Flags
- Approval of the issuance of 14,903,393 shares via pre-funded warrants suggests significant potential dilution for existing shareholders.
📋 Key Facts
- Annual Meeting held on November 25, 2025.
- Daniel E. Handley and Chuck Nuzum were elected as Class I directors until the 2028 Annual Meeting.
- Stockholders ratified the appointment of KPMG LLP as independent auditors for fiscal year ending Dec 31, 2025.
- Shareholders approved an amendment to the 2024 Equity Incentive Plan to increase available shares by 1,000,000.
- Shareholders approved the issuance of 14,903,393 shares via pre-funded warrants in accordance with Nasdaq Listing Rule 5635(a).
- Non-binding advisory vote on executive compensation was approved.
Predictive Oncology Inc. reports that it has regained compliance with Nasdaq's minimum stockholders' equity requirement following the closing of two PIPE transactions in October 2025.
🚩 Red Flags
- Historical delisting risk (non-compliance notice issued Nov 2024)
- High reliance on highly volatile crypto assets for capital infusion ($292.7M in-kind value vs $50.8M cash)
📋 Key Facts
- Company received a non-compliance notice from Nasdaq on November 20, 2024, regarding Nasdaq Listing Rule 5550(b)(1).
- Two private investment in public equity (PIPE) transactions closed on October 7, 2025.
- The PIPE transactions provided an aggregate of approximately $343.5 million ($50.8M cash and $292.7M in-kind crypto assets).
- Stockholders' equity is now reported to be in excess of $2.5 million, satisfying the requirement.
Predictive Oncology Inc. has issued an 8-K to announce a conference call and webcast regarding its Q3 2025 financial results and an update on its digital asset strategy.
🚩 Red Flags
- Mention of a 'digital asset strategy' in a biotech/oncology context may indicate a pivot or diversification that warrants closer scrutiny of capital allocation.
📋 Key Facts
- The company scheduled a conference call/webcast for November 17, 2025, at 9:00 a.m. ET.
- The meeting will discuss Q3 2025 financial results (ended September 30, 2025).
- The company will provide an update on its 'digital asset strategy'.
- An investor presentation was furnished as Exhibit 99.1.
Predictive Oncology Inc. issued an 8-K to furnish its quarterly financial results for the period ended September 30, 2025, and provided an update regarding its digital asset strategy.
📋 Key Facts
- Report date: November 14, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results and digital asset strategy updates.
- Signed by Josh Blacher, Chief Financial Officer.
Predictive Oncology Inc. has filed a prospectus supplement to amend its existing At-The-Market (ATM) offering program. The amendment updates the maximum share amount eligible for sale and clarifies the value limits under General Instruction I.B.6 of Form S-3.
🚩 Red Flags
- Continued use of ATM offering suggests a need for ongoing liquidity/capital raising.
- The company is operating under General Instruction I.B.6 restrictions, which applies to companies with lower public floats (often indicating micro-cap status).
📋 Key Facts
- Filed Prospectus Supplement on October 29, 2025, to amend the existing ATM Prospectus (originally dated May 21, 2024).
- The amendment updates the maximum amount of shares eligible for sale from and after October 29, 2025.
- As of Oct 29, 2025, the company had sold approximately $2,417,337 in securities via this program in the preceding 12 months.
- The current aggregate offering price limit is capped at $18,330,000 under General Instruction I.B.6 of Form S-3.
- If public float exceeds $75 million, the company will no longer be subject to these specific limits.
Predictive Oncology Inc. has announced the date, time, and location for its 2025 Annual Meeting of Stockholders. The meeting is scheduled for November 25, 2025, with a record date of October 24, 2025.
📋 Key Facts
- Annual Meeting Date: November 25, 2025
- Record Date for voting eligibility: October 24, 2025
- Location: DLA Piper LLP (US), Pittsburgh, Pennsylvania
- Proxy materials expected to be mailed on or about November 3, 2025
- Stockholder proposal deadline: October 26, 2025
Predictive Oncology Inc. announced the closing of two private placements on October 7, 2025, and the adoption of a new digital asset treasury strategy.
🚩 Red Flags
- Adoption of a 'digital asset treasury strategy' in a micro-cap biotech company often indicates high volatility or attempts to bolster the balance sheet through speculative assets rather than core operations.
📋 Key Facts
- Closed two separate private placement offerings on October 7, 2025.
- Adopted a formal digital asset treasury strategy.
- The filing includes a press release (Exhibit 99.1) detailing the placements and treasury strategy.
Predictive Oncology Inc. has entered into two major private placement agreements involving a cash offering of 55.2 million shares and a cryptocurrency offering of pre-funded warrants for up to 223.6 million shares. The company intends to use the proceeds to establish a digital asset treasury, primarily acquiring Aethir (ATH) tokens.
🚩 Red Flags
- Massive Dilution Risk: The issuance of up to ~235M total securities (shares + warrants) represents a significant increase in share count relative to current market cap.
- Highly Unconventional Financing: Using cryptocurrency/tokens as primary consideration for equity-linked instruments is high risk and non-standard for biotech/oncology firms.
- Complex Structure: Use of pre-funded warrants with $0.01 exercise prices effectively functions as immediate dilution upon registration.
- Regulatory/Counterparty Risk: The involvement of a Panama-based foundation (DCI) and the use of 'Locked Crypto' introduces significant jurisdictional and asset-recovery risks.
📋 Key Facts
- Cash Offering: Sale of ~55.2M common shares and ~11.5M pre-funded warrants at $0.7751 per share.
- Cryptocurrency Offering: Issuance of pre-funded warrants for up to ~223.6M shares in exchange for digital assets, primarily Aethir (ATH) tokens.
- Treasury Strategy: The company is pivoting/expanding into a 'digital asset treasury strategy' using proceeds to purchase ATH tokens.
- Closing Date: Expected on or about October 2, 2025.
- Registration Rights: Company must file resale registration statements within 15 days of closing.
- Side Letter: DCI Foundation (Panama) has provided a side letter regarding the delivery and release of 'Locked Crypto' assets.
Predictive Oncology Inc. announced two private placements and the adoption of a digital asset treasury strategy via press release on September 29, 2025.
🚩 Red Flags
- Adoption of a digital asset treasury strategy can introduce significant volatility and regulatory risk to the company's balance sheet.
- Private placements often involve potential dilution for existing shareholders.
📋 Key Facts
- Company issued a press release announcing two separate private placements.
- The company is adopting a 'digital asset treasury strategy' alongside its existing business lines.
- Filing includes Exhibit 99.1 containing the full details of the announcements.
Predictive Oncology Inc. has announced a 1-for-15 reverse stock split following stockholder approval on September 19, 2025. The split is intended to facilitate compliance with Nasdaq listing rules via a standby equity purchase agreement.
🚩 Red Flags
- Reverse stock split: Often used by micro-cap companies to artificially increase share price to meet minimum bid requirements for exchange listing.
- Nasdaq Compliance Risk: The filing explicitly mentions the $10M equity issuance is for purposes of complying with Nasdaq listing rule 5635, indicating a high risk of delisting if the stock price remains too low.
📋 Key Facts
- A 1-for-15 reverse stock split was approved by stockholders on September 19, 2025.
- The effective time of the reverse split is 5:00 PM ET on September 29, 2025.
- Trading on a reverse-split-adjusted basis is expected to begin September 30, 2025.
- Stockholders also approved a Nasdaq Proposal to issue up to $10,000,000 of common stock via a Standby Equity Purchase Agreement (SEPA) to comply with Nasdaq listing rule 5635.
- The company's ticker symbol remains 'POAI'.
Predictive Oncology Inc. announced the approval of significant Restricted Stock Unit (RSU) grants to its CEO and Interim CFO, scheduled to vest in full on October 31, 2025.
🚩 Red Flags
- Concentrated vesting date: All RSU grants for these executives vest simultaneously on October 31, 2025, which may create localized downward pressure on the stock price if executives sell immediately upon vesting.
- Interim status: The CFO is currently in an 'Interim' role, indicating potential leadership instability or transition in the finance department.
📋 Key Facts
- On September 9, 2025, the Board approved RSU grants under the 2024 Equity Incentive Plan.
- CEO Raymond F. Vennare was granted 124,959 RSUs.
- Interim CFO Josh Blacher was granted 97,000 RSUs.
- All RSUs are set to vest in full on October 31, 2025, contingent upon continued service.
Predictive Oncology Inc. completed a private placement of 543,544 common shares at $0.76 per share to an accredited investor on August 26, 2025. The company intends to use the approximately $413,093 in gross proceeds for working capital and general corporate purposes.
🚩 Red Flags
- Small capital raise ($413k) suggests limited liquidity runway
- Investor granted 100% participation rights in future offerings, which can be highly dilutive to existing shareholders
- Issuance of shares at a specific price point often indicates immediate need for cash (working capital)
📋 Key Facts
- Date of event: August 26, 2025
- Number of shares issued: 543,544 common stock shares
- Price per share: $0.76
- Gross proceeds: Approximately $413,093
- Investor granted a 100% participation right in future equity offerings through October 31, 2025
- Company must file a registration statement for the shares within 90 days of the agreement date
Predictive Oncology Inc. filed an 8-K to announce its quarterly financial results for the period ending June 30, 2025.
📋 Key Facts
- Reporting date: August 14, 2025
- Financial period covered: Quarter ended June 30, 2025
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
Predictive Oncology Inc. has received a reprieve from the Nasdaq Hearings Panel, granting an extension to regain compliance with listing requirements through December 8, 2025. The company is currently non-compliant regarding both stockholders' equity minimums and the minimum bid price requirement.
🚩 Red Flags
- Non-compliance with minimum stockholders' equity requirement ($2.5M).
- Non-compliance with the $1.00 minimum bid price requirement.
- Risk of delisting remains high if compliance is not achieved by Dec 8, 2025.
📋 Key Facts
- Nasdaq Hearings Panel granted an extension for continued listing until December 8, 2025.
- The company failed to meet the $2,500,000 stockholders’ equity requirement (Nasdaq Listing Rule 5550(b)(1)).
- The company's common stock closed below $1.00 for 30 consecutive business days, violating the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- A hearing before the Nasdaq Hearings Panel was held on July 17, 2025.
- The company is currently pursuing actions to satisfy compliance terms but provides no assurance of success.
Predictive Oncology is retrospectively revising its 2024 Form 10-K to reflect the sale of its 'Eagan Business' (STREAMWAY® product line) as discontinued operations. This follows an asset purchase agreement with DeRoyal Industries, Inc. closed in March 2025.
🚩 Red Flags
- Retrospective revision of historical financial statements (though noted as not a restatement, it changes the presentation of core business segments).
📋 Key Facts
- The company sold assets and liabilities related to the STREAMWAY® product line to DeRoyal Industries, Inc.
- The Eagan Business was operated through a wholly owned subsidiary, Skyline Medical Inc.
- Financial statements for fiscal years ended December 31, 2024, and 2023 are being retrospectively recast to reflect discontinued operations.
- Revisions apply specifically to Part I (Business), Part II Item 7 (MD&A), and Part II Item 8 (Financial Statements) of the 2024 Form 10-K.
Predictive Oncology Inc. received a deficiency notice from Nasdaq because its common stock closed below $1.00 for 30 consecutive business days, violating the Minimum Bid Price Requirement. The company has until January 5, 2026, to regain compliance.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential requirement for a reverse stock split to regain compliance
- Prolonged period of sub-$1.00 trading (30+ consecutive business days)
📋 Key Facts
- Nasdaq notified the company on July 8, 2025, of non-compliance with Nasdaq Marketplace Rule 5550(a)(2).
- The deficiency is due to the stock price closing below $1.00 for 30 consecutive business days.
- The company has a compliance period until January 5, 2026.
- Compliance can be achieved if the bid price closes at or above $1.00 for 10 consecutive business days.
- To qualify for an extension beyond Jan 5, 2026, the company may need to effect a reverse stock split.
Predictive Oncology Inc. entered into a $10 million Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD to provide flexible capital through the sale of common stock at a discount to market price.
🚩 Red Flags
- Equity Dilution: The SEPA allows the company to issue significant amounts of common stock at a 4% discount to VWAP, which is highly dilutive to existing shareholders.
- Death Spiral Characteristics: The pricing mechanism (96% of VWAP) and the ability for the company to direct 'Advances' are characteristic of death spiral financing structures often used by distressed micro-cap companies.
- Immediate Dilution: The company has already issued 120,482 shares as a commitment fee.
📋 Key Facts
- Entered into a SEPA with YA II PN, LTD on July 1, 2025.
- Total commitment amount is up to $10 million in common stock.
- Shares will be priced at 96% of the lowest daily VWAP over three consecutive trading days.
- The Company paid a $25,000 structuring fee and issued 120,482 shares (1.00% commitment fee) to the Investor.
- Includes an 'Exchange Cap' preventing issuance of more than 19.99% of outstanding shares without stockholder approval or specific price conditions ($0.83/share).
- Proceeds are intended for working capital and general corporate purposes.
Predictive Oncology Inc. has received a notice from Nasdaq stating it will be delisted due to failure to meet the $2,500,000 minimum stockholders' equity requirement. The company has filed an appeal to stay the suspension of trading.
🚩 Red Flags
- Delisting notice from Nasdaq (failure to meet minimum stockholders' equity requirement).
- Failure of previous compliance plan within the 180-day extension period.
- Potential for trading suspension on June 18, 2025.
- Significant risk that an appeal may not be granted or that compliance cannot be maintained even if a stay is issued.
📋 Key Facts
- Received notice from Nasdaq on June 9, 2025, regarding delisting for failing to meet the $2,500,000 stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)).
- The company failed to complete its previously submitted plan of compliance within the provided 180-day extension period.
- Trading suspension is scheduled for June 18, 2025, unless an appeal is requested by June 16, 2025.
- The Company has officially submitted a hearing request to Nasdaq’s Hearings Panel to stay the suspension and appeal the determination.
Predictive Oncology Inc. has amended its At-The-Market (ATM) prospectus supplement to update the maximum share amount eligible for sale and clarify selling limits under General Instruction I.B.6 of Form S-3.
🚩 Red Flags
- Ongoing use of ATM offering suggests a need for continuous liquidity/cash runway management.
📋 Key Facts
- Amended ATM Prospectus dated June 2, 2025, supplementing the May 21, 2024 prospectus.
- The amendment updates the maximum amount of shares eligible to be sold from and after June 2, 2025.
- Current selling limit under General Instruction I.B.6 is capped at an aggregate offering price of $3,398,000.
- As of June 2, 2025, the company has already sold approximately $684,467 worth of securities via this ATM program.
- The company notes that if public float exceeds $75.0 million, it will no longer be subject to General Instruction I.B.6 limits.
Predictive Oncology Inc. filed an 8-K to announce its quarterly financial results for the period ending March 31, 2025.
📋 Key Facts
- Report date: May 15, 2025
- Reporting period: Quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) detailing results of operations and financial condition.
- Interim CFO Josh Blacher signed the report.
Predictive Oncology Inc. (POAI) filed an amendment to its 8-K to clarify that it has officially discontinued merger discussions with Renovaro Inc. (RENB). The company explicitly refutes RENB's claims of a 'binding agreement,' stating the Letter of Intent expired on March 31, 2025.
🚩 Red Flags
- Public dispute with a counterparty (RENB) regarding the existence of a binding agreement.
- Potential for market confusion/volatility due to conflicting statements between POAI and RENB.
📋 Key Facts
- The Company is amending an April 7, 2025 filing to move information from Item 7.01 to Item 8.01.
- Discussions with Renovaro Inc. (RENB) regarding a proposed merger have been discontinued.
- A Letter of Intent was originally entered into on January 1, 2025 and extended via an agreement on February 28, 2025.
- The Letter of Intent expired/terminated on March 31, 2025.
- POAI denies RENB's April 4, 2025 press release claim that a 'binding merger agreement' exists.
Predictive Oncology Inc. (POAI) has officially terminated discussions and a Letter of Intent (LOI) with Renovaro Inc. (RENB). The company explicitly denies RENB's claims of a binding merger agreement, stating the LOI expired on March 31, 2025.
🚩 Red Flags
- Public dispute/misrepresentation: RENB issued a press release claiming a binding merger exists, which POAI explicitly denies. This indicates significant friction or potential misinformation from the counterparty.
- Failed M&A activity: The termination of a long-standing LOI (since Jan 1, 2025) suggests failed strategic growth via acquisition.
📋 Key Facts
- The Letter of Intent (LOI) between POAI and RENB terminated on March 31, 2025.
- POAI clarifies that no merger agreement was ever entered into with RENB.
- POAI refutes a press release from RENB dated April 4, 2025, which claimed a 'binding agreement' existed.
- The LOI had previously been extended via an agreement on February 28, 2025.
Predictive Oncology Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a placeholder for the press release containing the company's annual performance data.
📋 Key Facts
- Report date: April 1, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Interim CFO Josh Blacher signed the report.
Predictive Oncology Inc. has entered into an agreement to sell its STREAMWAY® product line and related assets/liabilities to DeRoyal Industries, Inc. This divestiture involves the sale of medical fluid disposal business operations previously held under its Skyline Medical Inc. subsidiary.
🚩 Red Flags
- Divestiture of a product line/operating segment may indicate a strategic shift or a need for immediate liquidity given the relatively low purchase price ($625k).
📋 Key Facts
- The transaction closed on March 14, 2025.
- Total purchase price is $625,000 in cash.
- Buyer (DeRoyal Industries, Inc.) will assume certain liabilities including office/warehouse leases and accounts payable due within 90 days.
- Assets sold include inventory, prototypes, intellectual property (trademarks, patents), customer contracts, and tangible personal property.
- The business being divested was previously reported in the Company's Eagan operating segment.
Predictive Oncology Inc. has entered into an extension agreement with Renovaro, Inc. regarding a proposed acquisition of all Predictive Oncology capital stock. The deal's termination date is extended to March 31, 2025, and includes immediate share purchases by Renovaro.
🚩 Red Flags
- Extension of LOI suggests potential delays or renegotiations in the merger process.
- Elimination of Renovaro's previous obligation to acquire certain shares of common stock indicates a change in deal terms/structure.
📋 Key Facts
- Extension Agreement signed on February 28, 2025, extending the LOI expiration from Feb 28, 2025, to March 31, 2025.
- Renovaro is acquiring 467,290 shares of Predictive Oncology for $500,000 immediately.
- Renovaro agreed to purchase an additional 901,298 shares for $964,389 upon execution of a definitive agreement.
- The transaction involves the filing of a Form S-4 Registration Statement by Renovaro.
Predictive Oncology Inc. completed a registered direct offering of 363,336 shares at $1.50 per share to institutional and accredited investors. The gross proceeds from the offering total approximately $545,004, intended for working capital and general corporate purposes.
🚩 Red Flags
- Dilutive event: Issuance of new common stock to institutional investors.
- Placement agent warrants: Significant warrant coverage (7%) issued to the placement agent, which can lead to further dilution upon exercise.
📋 Key Facts
- Offered 363,336 shares of common stock at a price of $1.50 per share.
- Gross proceeds are approximately $545,004 before fees.
- The offering closed on February 19, 2025.
- H.C. Wainwright & Co., LLC acted as the placement agent with an aggregate fee of 8% (7% transaction fee + 1% management fee) plus $15,000 in legal fees.
- Placement Agent Warrants were issued to H.C. Wainwright & Co., LLC for up to 25,434 shares at an exercise price of $1.875 per share (125% of the offering price).
- Warrants are exercisable for five years.
Predictive Oncology Inc. held its Annual Meeting of Stockholders on December 30, 2024, to elect directors and ratify the auditor. While most proposals passed, shareholders failed to approve a non-binding advisory resolution regarding executive compensation.
🚩 Red Flags
- Shareholders voted against the Say-on-Pay advisory resolution regarding executive compensation.
📋 Key Facts
- Annual Meeting held on December 30, 2024.
- Elected Raymond F. Vennare and Veena Rao, Ph.D. as Class III directors for three-year terms expiring in 2027.
- Ratified the appointment of KPMG LLP as independent auditor for 2024 (2,725,975 votes 'For').
- Approved the 2024 Equity Incentive Plan.
- Failed to approve the non-binding advisory resolution on executive compensation (613,375 'For' vs. 683,986 'Against').
Predictive Oncology Inc. has entered into a binding Letter of Intent (LOI) to be acquired by Renovaro, Inc. in an all-stock transaction. The deal involves a 1:1 exchange for newly created preferred stock with specific redemption and conversion features.
🚩 Red Flags
- Contingent on Renovaro raising $15 million in capital, introducing significant deal uncertainty.
- The 'poison pill' style clause: If shareholders reject the merger, the company loses its core intellectual property (biobank and 3D models) via a royalty-free license to the acquirer.
- Redemption price of $3.00 per share may be significantly different from current market trading prices, creating arbitrage or downside risk for holders.
📋 Key Facts
- Predictive Oncology will merge into Renovaro in exchange for a new series of Renovaro preferred stock.
- Exchange ratio is 1:1 (Predictive Oncology common stock to Renovaro preferred stock).
- Preferred stock is automatically redeemable for $3.00 per share after 18 months.
- Conversion feature: Holders can convert to Renovaro common stock at a 1:1 ratio if Renovaro's stock trades $\ge$ $4.50 for 30 consecutive trading days.
- Redemption clause: Renovaro can redeem preferred stock for $3.00 cash if Renovaro stock is $\le$ $3.00 or if conversion isn't requested within 30 days of eligibility.
- Renovaro will purchase up to 2.33 million shares at $1.07/share if Series A and B warrants are not exercised by Jan 15, 2025.
- The merger is contingent upon Renovaro raising a minimum of $15 million in funding and shareholder approval.
- Failure to obtain shareholder approval grants Renovaro a two-year exclusive royalty-free license to Predictive Oncology's biobank and 3D cell culture models.
Predictive Oncology Inc. received a notice from Nasdaq stating it is non-compliant with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. As of September 30, 2024, the company's stockholders' equity was $1.97 million, falling below the required $2.5 million threshold.
🚩 Red Flags
- Delisting notice for failure to meet minimum stockholders' equity requirement.
- Failure to meet alternative compliance standards (market value and net income).
- Potential delisting risk if a compliance plan is not accepted or executed within the extension period.
📋 Key Facts
- Received Nasdaq notice on November 20, 2024.
- Stockholders' equity as of Sept 30, 2024: $1,966,969 (Requirement: $2.5 million).
- Company failed alternative compliance standards regarding market value ($35M) and net income ($500k).
- Deadline to submit a plan to regain compliance is January 6, 2025.
- If a plan is accepted, the company may receive an extension of up to 180 days to evidence compliance.
Predictive Oncology Inc. filed an 8-K to announce its quarterly financial results for the period ending September 30, 2024.
📋 Key Facts
- The filing was made on November 13, 2024.
- The report covers the quarter ended September 30, 2024.
- The company issued a press release (Exhibit 99.1) containing the financial results.
Predictive Oncology Inc. received a deficiency notice from Nasdaq because its common stock closed below $1.00 per share for 30 consecutive business days, violating the Minimum Bid Price Requirement.
🚩 Red Flags
- Delisting notice from Nasdaq
- Potential requirement for a reverse stock split to regain compliance
- Stock price has been consistently below $1.00 (penny stock territory)
📋 Key Facts
- The company is currently non-compliant with Nasdaq Marketplace Rule 5550(a)(2).
- The deficiency was triggered by the stock closing below $1.00 for 30 consecutive business days.
- The company has a compliance period of 180 days, expiring on March 18, 2025.
- Compliance can be regained if the bid price closes at or above $1.00 for 10 consecutive business days before the deadline.
- To qualify for an additional compliance period, the company may need to effect a reverse stock split.
Predictive Oncology Inc. filed an 8-K to announce its financial results for the quarterly period ended June 30, 2024.
📋 Key Facts
- The filing relates to the announcement of financial results for the quarter ending June 30, 2024.
- The report was filed on August 14, 2024.
- The company is listed on the Nasdaq Capital Market under the symbol POAI (noted in text as AGPU/POAI transition).
- Interim CFO Josh Blacher signed the filing.
Predictive Oncology Inc. entered into agreements to facilitate the immediate exercise of existing warrants at a significantly reduced price, raising approximately $1.26 million in gross proceeds. In exchange for this cash infusion, the company issued new Series A and Series B warrants to holders with low exercise prices ($1.07) and additional warrants to the placement agent.
🚩 Red Flags
- Extreme warrant dilution: The reduction of exercise price from $14.00 to $1.32 represents a massive downward adjustment, signaling significant distress or an attempt to prevent expiration/default.
- Death spiral characteristics: The issuance of new warrants (Series A and B) at very low strike prices ($1.07) creates substantial future dilution for existing shareholders.
- Heavy reliance on dilutive financing: The company is using 'warrant inducement' to secure immediate, albeit small, amounts of cash ($1.26M).
- High transaction costs: Placement agent fees and warrant compensation represent a significant portion of the capital raised.
📋 Key Facts
- Existing warrants (issued Feb/May 2021 & June 2021) were exercised at a reduced price of $1.32 per share, down from an original exercise price of $14.00.
- Gross proceeds from the warrant exercise totaled approximately $1.26 million.
- Company issued new Series A Warrants (5-year term) and Series B Warrants (18-month term) with an exercise price of $1.07 per share to existing holders.
- H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving cash fees totaling 8% plus expenses and compensation warrants for 67,068 shares at $1.65/share.
- Proceeds are intended for working capital and general corporate purposes.
Predictive Oncology Inc. filed an 8-K to announce a press release issued on May 28, 2024. The filing does not contain specific financial data or material event details in the body text, referring instead to Exhibit 99.1.
📋 Key Facts
- Report date: May 28, 2024
- Filing date: May 30, 2024
- The company issued a press release on May 28, 2024 (Exhibit 99.1)
- Interim CFO Josh Blacher signed the report
Predictive Oncology Inc. filed an 8-K to announce its financial results for the quarterly period ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting date: May 15, 2024.
- Period covered: Quarter ended March 31, 2024.
- The company issued a press release as Exhibit 99.1 to accompany the results.
Predictive Oncology Inc. entered into an 'at the market' (ATM) sales agreement with H.C. Wainwright & Co., LLC to facilitate the sale of up to $3,696,000 in common stock.
🚩 Red Flags
- Potential dilution for existing shareholders through the issuance of new common stock.
- ATM offerings are often used by micro-cap companies to raise immediate working capital, which can signal liquidity needs.
📋 Key Facts
- Entered into ATM Sales Agreement on May 3, 2024.
- Sales agent: H.C. Wainwright & Co., LLC.
- Maximum offering amount: $3,696,000.
- Wainwright compensation: 3.0% of the gross sales price.
- Issuance is subject to the effectiveness of a Form S-3 registration statement filed on May 3, 2024.
Predictive Oncology Inc. has dismissed its independent auditor, BDO USA, P.C., and engaged KPMG LLP for the fiscal year ending December 31, 2024. The dismissal follows a period where the previous auditor issued an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
🚩 Red Flags
- Going concern language: The 2023 BDO Report contained an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
- Material weaknesses in internal control over financial reporting (accounting resources and IT general controls).
- History of reverse stock split adjustments noted in recent audits.
📋 Key Facts
- Effective April 3, 2024, BDO USA, P.C. was dismissed as the independent auditor.
- KPMG LLP has been engaged for the fiscal year ending December 31, 2024 (pending standard client evaluation).
- The previous auditor's report for the year ended Dec 31, 2023, contained an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
- BDO audited adjustments to 2022 financial statements related to a reverse stock split and changes in reportable segments.
- Material weaknesses were identified in internal control over financial reporting regarding inadequate accounting resources for complex transactions and IT general controls (user access/segregation of duties).
Predictive Oncology Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the release of their annual earnings press release.
📋 Key Facts
- Report date: March 28, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes an earnings press release as Exhibit 99.1
- Interim CFO Josh Blacher signed the report
This is an 8-K/A amendment regarding the results of a shareholder advisory vote. The company's stockholders voted to maintain annual 'Say-on-Pay' votes, and the Board has committed to conducting these votes every year for the foreseeable future.
📋 Key Facts
- The filing is an amendment (8-K/A) to an original 8-K filed on December 2, 2022.
- Stockholders voted in favor of conducting 'Say-on-Pay' votes every year rather than every two or three years.
- The Board of Directors will re-evaluate the frequency determination after the next Say-on-Frequency Proposal, which must occur no later than the 2028 annual meeting.
Predictive Oncology Inc. announced the departure of its Chief Business Officer, Pamela Bush, Ph.D., MBA, effective February 15, 2024. The company is currently searching for a replacement as part of its corporate development strategy.
🚩 Red Flags
- Departure of a key executive (Chief Business Officer) in a micro-cap biotech company can sometimes signal internal strategic shifts or friction, though not explicitly stated here.
📋 Key Facts
- Pamela Bush, Ph.D., MBA, will leave her role as Chief Business Officer on February 15, 2024.
- The departure was by mutual agreement between the Company and Dr. Bush.
- The company has initiated a search to fill the Chief Business Officer position.
Predictive Oncology Inc. reported the results of its Annual Meeting of Stockholders held on December 28, 2023. The meeting included the election of three Class II directors and the ratification of BDO USA, P.C. as independent auditors.
🚩 Red Flags
- Shareholders rejected the 2023 Equity Incentive Plan, which may indicate dissatisfaction with dilution or compensation structures.
- High number of Broker Non-Votes (1,023,553) across all items suggests significant institutional or non-participating shareholder presence.
📋 Key Facts
- Annual Meeting held on December 28, 2023.
- Three Class II directors elected: Gregory St. Clair, Sr., Nancy Chung-Welch, Ph.D., and Matthew J. Hawryluk, Ph.D.
- BDO USA, P.C. was ratified as the independent auditor for 2023 with 1,628,338 votes in favor.
- The proposal to approve the 2023 Equity Incentive Plan failed to pass (432,129 'For' vs 435,447 'Against').
- A non-binding advisory resolution on executive compensation was approved.